43 results on '"Soumoy L"'
Search Results
2. Isoformes 1 et 4 du LDH plasmatique comme biomarqueurs pronostiques et de réponse au traitement dans le mélanome
- Author
-
Fredeau, L., primary, Soumoy, L., additional, Quidville, V., additional, Roy, S., additional, Chehade, F., additional, and Robert, C., additional
- Published
- 2022
- Full Text
- View/download PDF
3. 3PC-068 Long term stability of co-administration of bumetanide and scopolamine for the palliative care unit
- Author
-
Catry, E, primary, Colsoul, ML, additional, Closset, M, additional, Hubert, J, additional, Soumoy, L, additional, Bihin, B, additional, Jamart, J, additional, Hecq, JD, additional, and Galanti, L, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers
- Author
-
Colsoul, M. L., primary, Breuer, A., additional, Goderniaux, N., additional, Hecq, J. D., additional, Soumoy, L., additional, Bihin, B., additional, Jamart, J., additional, and Galanti, L., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Second audit de prescription, d’administration et de suivi des alimentations parentérales au centre hospitalier universitaire de Mont-Godinne. Intérêt de l’implication d’une diététicienne
- Author
-
Dauw, G., primary, Noël, D., additional, Lacrosse, D., additional, Vanesse, V., additional, Hecq, J.-D., additional, Soumoy, L., additional, and Michel, C., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Long-Term Stability of Lorazepam in Sodium Chloride 0.9% Stored at Different Temperatures in Different Containers.
- Author
-
Colsoul, M. L., Breuer, A., Goderniaux, N., Hecq, J. D., Soumoy, L., Bihin, B., Jamart, J., and Galanti, L.
- Subjects
GLASS ,ANALYTICAL chemistry techniques ,DRUG stability ,DOSAGE forms of drugs ,DRUG storage ,HIGH performance liquid chromatography ,INCOMPATIBLES (Pharmacy) ,LORAZEPAM ,SALT ,SYRINGES ,TEMPERATURE ,MEDICATION therapy management ,DESCRIPTIVE statistics - Abstract
Background and Objective: Infusion containing lorazepam is used by geriatric department to limit anxiety disorders in the elderly. Currently, these infusions are prepared according to demand by the nursing staff, but the preparation in advance in a centralized service could improve quality of preparation and time management. The aim of this study was to investigate the long-term stability of this infusion in polypropylene syringes stored at 5 ± 3°C. Then, results obtained were compared with stability data of lorazepam in syringes stored at room temperature, glass bottles at 5 ± 3°C, and glass bottles at room temperature. Method: Eight syringes and 6 bottles of infusion were prepared by diluting 1 mL lorazepam 4 mg in 23 mL of NaCl 0.9% under aseptic conditions. Five syringes and 3 bottles were stored at 5 ± 3°C and 3 syringes and 3 bottles were stored at room temperature for 30 days. During the storage period, particle appearance or color change were periodically checked by visual and microscope inspection. Turbidity was assessed by measurements of optical density (OD) at 3 wavelengths (350 nm, 410 nm, 550 nm). The stability of pH was also evaluated. The lorazepam concentrations were measured at each time point by high-performance liquid chromatography with ultraviolet detector at 220 nm. Results: Solutions were physically unstable in syringes at 5 ± 3°C after 4 days: crystals and a drop of OD at 350 nm were observed. However, pH was stable. After 2 days, solutions were considered as chemically unstable because a loss of lorazepam concentration higher than 10% was noticed: the lower 1-sided confidence limit at 95% was below 90% of the initial concentration. To assess temperature and polypropylene influence, results were compared with those obtained for syringes at room temperature and bottles at 5 ± 3°C and room temperature. Precipitation, drop of OD at 350 nm, and chemical instability were observed in all conditions. Conclusion: Solutions of lorazepam were unstable after 2 days in syringes at 5 ± 3°C. Preparation in advance appears, therefore, not possible for the clinical use. Storage conditions (temperature and form) do not improve the stability. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. 3PC-028 Stability of concentrated solutions of salbutamol hydrochloride in syringes for administration in the intensive care unit
- Author
-
Hecq, JD, primary, Lardinois, B, additional, Braibant, M, additional, Baltzys, A, additional, Bihin, B, additional, Jamart, J, additional, Soumoy, L, additional, and Galanti, L, additional
- Published
- 2018
- Full Text
- View/download PDF
8. 3PC-007 Determination of the physicochemical stability of amiodarone hydrochloride in syringes for intensive care unit
- Author
-
Hecq, JD, primary, Lardinois, B, additional, Dimitrio, A, additional, Bihin, B, additional, Jamart, J, additional, Soumoy, L, additional, and Galanti, L, additional
- Published
- 2018
- Full Text
- View/download PDF
9. Physical stability of highly concentrated injectable drugs solutions used in intensive care units.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, UCL - (MGD) Laboratoire de biologie clinique, Closset, M, Hecq, Jean-Daniel, Soumoy, L, Simar, J, Gonzalez, E, Charlet, L, Declave, C, Gillet, P, Galanti, Laurence, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, UCL - (MGD) Laboratoire de biologie clinique, Closset, M, Hecq, Jean-Daniel, Soumoy, L, Simar, J, Gonzalez, E, Charlet, L, Declave, C, Gillet, P, and Galanti, Laurence
- Abstract
The intensive care department of the institution use drug solutions within higher concentration to avoid fluid overload. The purpose of the study is to prove the physical stability of different injectable drugs within high concentration (amiodarone 25mg/mL, isosorbide 0.60mg/mL, lorazepam 0.16mg/mL, noradrenalin 0.120 and 0.240mg/mL, salbutamol 0.06mg/mL and sodium valproate 12mg/mL) to ensure the patients safety.
- Published
- 2017
10. PP-032 Anticipated circuit of anticancer intravenous chemotherapies prescription and preparation in a day hospital: observational study assessing the impact of the new workflow for hospital pharmacy
- Author
-
Langhendries, C, primary, Spinewine, A, additional, Soumoy, L, additional, Hecq, JD, additional, Andre, M, additional, D’Hondt, L, additional, Duplaquet, F, additional, Jamart, J, additional, and Gillet, P, additional
- Published
- 2017
- Full Text
- View/download PDF
11. Etude préliminaire pour l’implémentation d’un dose-banding de chimiothérapie anticancéreuse
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Soumoy, L, Pirlot, C, Decoster C, Gillet , P, Hecq, Jean-Daniel, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Département de pharmacie, Soumoy, L, Pirlot, C, Decoster C, Gillet , P, and Hecq, Jean-Daniel
- Abstract
« Dose-banding » is a concept of cytotoxic drugs standardization allowing the preparation in advance of standardized rounded doses (SRD) covering the most frequently prescribed doses rounded to ± 5%. Standard doses will be prepared in advance by batch in order to increase production capacity and at the same time to regulate pharmacy workflow as well as to reduce patient waiting time.
- Published
- 2015
12. PP-014 Preliminary study to implement dose banding in a teaching hospital
- Author
-
Soumoy, L, primary, Pirlot, C, additional, Decoster, C, additional, Leonard, N, additional, Gillet, P, additional, and Hecq, JD, additional
- Published
- 2014
- Full Text
- View/download PDF
13. Automated Compounding of Intravenous Therapy in European Countries: A Review in 2019
- Author
-
Soumoy Laura and Hecq Jean-Daniel
- Subjects
aseptic compounding ,centralized intravenous admixtures services ,compounding automation ,robot ,Therapeutics. Pharmacology ,RM1-950 ,Pharmaceutical industry ,HD9665-9675 - Abstract
Automated compounding systems appeared on the market during these last 15 years as an alternative for manual compounding of intravenous (IVD) drugs. A literature review was conducted on reconstitution of IVD. The following methods were identified: manual, semi- automatic and automatic. A classification was carried out in three categories: automatic syringes, peristaltic pumps, and compounding doses robots. The number of compounding robots is increasing. A table describes the different features of each device. The ampuls cannot be supported by these robots. Large doses vials improve the time of reconstitution compared to current dosage vials. Advantages of automated preparation are: higher consistency of process and products, higher accuracy of products, Integrated digitized processing, precise, complete documentation, reduced effort and wrist injuries, reduced personnel requirement, increased worker satisfaction. Disadvantages of automated preparation are: risk of failure/down time, dependency on power supply, software (updates), high investment costs/high maintenance costs, specialized personnel with additional training, decreased worker satisfaction (early adopter), complexity when products are switched or added, potential for new errors. This review allows the potential user to know the current availability on the market.
- Published
- 2019
- Full Text
- View/download PDF
14. Stability of Concentrated Solution of Vancomycin Hydrochloride in Syringes for Intensive Care Units
- Author
-
Godet Marie, Simar Joanna, Closset Mélanie, Hecq Jean-Daniel, Braibant Maximilien, Soumoy Laura, Gillet Patricia, Jamart Jacques, Bihin Benoît, and Galanti Laurence
- Subjects
vancomycin infusions ,concentrated solutions ,high performance liquid chromatography ,physicochemical stability ,syringe ,intensive care units ,Therapeutics. Pharmacology ,RM1-950 ,Pharmaceutical industry ,HD9665-9675 - Abstract
Vancomycin is increasingly administrated by continuous infusion. But the treatment of patient in intensive care need restricted volume to prevent fluid overload. The aim of the study was to evaluate the physical and chemical stability of solutions of a high concentration of vancomycin hydrochloride in 5 % glucose or 0.9 % NaCl.
- Published
- 2018
- Full Text
- View/download PDF
15. Développement de quelques Fagaceae japonaises; germination, modèle architectural et systématique
- Author
-
Soumoy, L., primary, Thiébaut, B., additional, and Sérey, I., additional
- Published
- 1996
- Full Text
- View/download PDF
16. 3PC-028 Stability of concentrated solutions of salbutamol hydrochloride in syringes for administration in the intensive care unit
- Author
-
Hecq, JD, Lardinois, B, Braibant, M, Baltzys, A, Bihin, B, Jamart, J, Soumoy, L, and Galanti, L
- Abstract
BackgroundIn order to avoid fluid overload, the use of more concentrated drug solutions in intensive care units is common.PurposeQuantifying the physicochemical stability of concentrated solution of salbutamol in polypropylene syringe during 30 days at 5°C±3°C with protection from light.Material and methodsFive syringes of 50 ml, containing 0.060 mg/ml of salbutamol in 0.9% NaCl were prepared and stored at 5°C±3°C with protection from light during 30 days. Immediately after preparation and periodically during the storage, salbutamol concentrations were measured by an ultra performance liquid chromatography (UPLC). Spectrophotometric absorbance at different wavelengths, pH measurement, and visual and microscopic observations were also performed.ResultsAll solutions were physicochemically stable during the whole period storage at 5°C±3°C: no colour change, turbidity, precipitation or opacity, no significant pH variations or optic densities were observed in the solutions. Any crystals were seen by microscopic analysis. Solutions are considered chemically stable, as the lower limit of the 95% unilateral confidence interval on the mean remained above 90% of the initial concentration for at least 30 days.ConclusionSolutions of salbutamol 0.060 mg/ml in syringe of 0.9% NaCl are physically and chemically stable for at least 30 days when stored in syringes at 5°C±3°C with protection from light, and may be prepared in advance by a Centralised IntraVenous Admixture Service (CIVA).Reference and/or Acknowledgements1. Closset M, Hecq JD, Soumoy L, Simar J, Gonzalez E, Charlet L, Declave C, Gillet P, Galanti L. Physical stability of highly concentrated injectable drugs solutions used in intensive care units. Ann Pharm Fr201713 Feb;S0003–4509(16):30055–4. doi: 10. 1016/j. pharma. 2016. 12. 004No conflict of interest
- Published
- 2018
- Full Text
- View/download PDF
17. 3PC-007 Determination of the physicochemical stability of amiodarone hydrochloride in syringes for intensive care unit
- Author
-
Hecq, JD, Lardinois, B, Dimitrio, A, Bihin, B, Jamart, J, Soumoy, L, and Galanti, L
- Abstract
BackgroundThe intensive care unit (ICU) use drug solutions with higher concentration to avoid fluid overload.PurposeTo determine the physicochemical stability of a concentrated solution of amiodarone in a polypropylene syringe during 28 days at 5°C±3°C with protection from light.Material and methodsFive syringes of 50 ml, containing 25 mg/ml of amiodarone in 0.9% NaCl were prepared and stored at 5°C±3°C with protection from light during 28 days. Immediately after preparation and periodically during the storage, amiodarone concentrations were measured by an ultra performance liquid chromatography (UPLC). Spectrophotometric absorbance at different wavelengths, pH measurement, and visual and microscopic observations were also performed.ResultsAll solutions were physico-chemically stable during the whole period storage at 5°C±3°C: no colour change, turbidity, precipitation or opacity, no significant pH variations or optic densities were observed in the solutions. Any crystals were seen by microscopic analysis. Solutions are considered chemically stable as the lower limit of the 95% unilateral confidence interval on the mean remained above 90% in the initial concentration for at least 28 days.ConclusionSolutions of amiodarone 25 mg/ml in syringes of 0.9% NaCl are physically and chemically stable for at least 28 days when stored in syringes at 5°C±3°C with protection from light and may be prepared in advance by a Centralised IntraVenous Admixture Service (CIVA).Reference and/or Acknowledgements1. Simar J, Delcave C, Godet M, Decoster C, Gillet P, Bihin B, Jamart J, Galanti LM, Hecq JD. Stabilité physique du chlorhydrate d’amiodarone dans des seringues de glucose 5% pour perfusion. Journal de Pharmacie de Belgique2016;98(1):24–25.No conflict of interest
- Published
- 2018
- Full Text
- View/download PDF
18. New Hybrid Organic-inorganic Multifunctional Materials Based on Polydopamine-like Chemistry
- Author
-
Carmela Aprile, Loraine Soumoy, Francesco Giacalone, Leonarda F. Liotta, Michelangelo Gruttadauria, Carla Calabrese, Calabrese C., Liotta L.F., Soumoy L., Aprile C., Giacalone F., and Gruttadauria M.
- Subjects
Heterogeneous catalysis ,Silanes ,Chemistry ,Organic Chemistry ,Supported catalysts ,Nanotechnology ,polydopamine like chemistry ,Settore CHIM/06 - Chimica Organica ,Dopamines ,chemistry.chemical_compound ,Immobilization ,Organic inorganic ,hybrid organic-inorganic multifunctional materials - Abstract
Taking inspiration from the chemistry of dopamine, a simple and economic synthetic approach toward the synthesis of a series of silica-based polydopamine-like materials has been developed. Mild conditions and easy manipulation are the strongest aspects of this methodology. Such hybrid materials were successfully used as recyclable catalysts for Knoevenagel reactions., A simple one-pot procedure under mild conditions has been developed with the aim of preparing a set of hybrid organic-inorganic multifunctional materials. This procedure is based on the use of catechol and KIO 4 as oxidizing agent in conjunction with 3-aminopropyl-, substituted 3-aminopropyl- and 3-methylimidazolium-1-trimethoxypropylsilane mimicking polydopamine-like chemistry. Reactions were carried out in water at room temperature and 70 °C to give fifteen materials that were characterised by using several techniques (nitrogen physisorption, TGA, XPS, 13C and 29Si CP-MAS NMR, IR, pH PZC). Knoevenagel reaction was chosen as a good probe to investigate the availability of functional groups on the surface of the materials. The most active catalytic materials were tested in recycling procedures. Such simple procedure is of broad interest for the scientific community and it open the doors to the development of new hybrid organic-inorganic multifunctional materials for several purposes.
- Published
- 2021
19. Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C.
- Author
-
Kinet-Poleur A, Colsoul ML, Catry E, Bihin BP, Sneyers BE, Hubert J, Jamart J, Soumoy L, Galanti LM, Hecq JD, and Closset M
- Abstract
Objective: Esketamine (Vesierra) is a molecule, used alone or in combination, to induce and maintain general anaesthesia and to relieve pain in emergency medicine. The aim of this study is to evaluate the long-term physicochemical stability of a 1 mg/mL solution of esketamine diluted in 0.9% sodium chloride (NaCl) and stored in polypropylene syringes at 5±3°C during 65 days (64+1 day at 22±3°C) and 72 hours at 22±3°C (room temperature), in order to centralise preparation under aseptic conditions in hospital pharmacy., Methods: Ten syringes were prepared under aseptic conditions. Five syringes were stored at 22±3°C for 3 days, and the five others were stored at 5±3°C for 64 days (+ 1 day at room temperature). The stability was periodically investigated. Particle appearance or colour changes were checked by visual inspection. A research of crystals was performed under the microscope. pH was followed to assess its stability. The turbidity of the solutions was estimated by a measure of optical densities at 350, 410 and 550 nm. The molecule concentrations were measured by ultra-high performance liquid chromatography (UHPLC) coupled with a photodiode array detection (PDA), using a newly developed method., Results: Based on microscopic examination, no crystals were observed, during the observation period. pH and absorbances at 350, 410 and 550 nm were also stable. Macroscopically, there was no change in colour and appearance of opacity, turbidity or precipitation. Statistical analysis indicates that 1 mg/mL esketamine solutions were chemically stable under these conditions, given that less than 5% of the solutions have lost more than 10% of their initial content during the study based on the prediction interval., Conclusions: One mg/mL solutions of esketamine hydrochloride are physically and chemically stable after production, for at least 72 hours at 22±3°C and 64 days at 5±3°C (+ 1 day at room temperature)., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
20. ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.
- Author
-
Soumoy L, Genbauffe A, Mouchart L, Sperone A, Trelcat A, Mukeba-Harchies L, Wells M, Blankert B, Najem A, Ghanem G, Saussez S, and Journe F
- Abstract
Despite advancements in treating metastatic melanoma, many patients exhibit resistance to targeted therapies. Our study focuses on ATP1A1, a sodium pump subunit associated with cancer development. We aimed to assess ATP1A1 prognostic value in melanoma patients and examine the impact of its ligand, bufalin, on melanoma cell lines in vitro and in vivo. High ATP1A1 expression (IHC) correlated with reduced overall survival in melanoma patients. Resistance to BRAF inhibitor was linked to elevated ATP1A1 levels in patient biopsies (IHC, qPCR) and cell lines (Western blot, qPCR). Additionally, high ATP1A1 mRNA expression positively correlated with differentiation/pigmentation markers based on data from The Cancer Genome Atlas (TCGA) databases and Verfaillie proliferative gene signature analysis. Bufalin specifically targeted ATP1A1 in caveolae, (proximity ligation assay) and influenced Src phosphorylation (Western blot), thereby disrupting multiple signaling pathways (phosphokinase array). In vitro, bufalin induced apoptosis in melanoma cell lines by acting on ATP1A1 (siRNA experiments) and, in vivo, significantly impeded melanoma growth using a nude mouse xenograft model with continuous bufalin delivery via an osmotic pump. In conclusion, our study demonstrates that ATP1A1 could serve as a prognostic marker for patient survival and a predictive marker for response to BRAF inhibitor therapy. By targeting ATP1A1, bufalin inhibited cell proliferation, induced apoptosis in vitro, and effectively suppressed tumor development in mice. Thus, our findings strongly support ATP1A1 as a promising therapeutic target, with bufalin as a potential agent to disrupt its tumor-promoting activity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags.
- Author
-
Closset M, Onorati S, Colsoul ML, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq JD, Odou P, and Galanti L
- Subjects
- Humans, Drug Packaging, Drug Stability, Drug Storage, Chromatography, High Pressure Liquid, Fluorouracil, Sodium Chloride chemistry
- Abstract
Background: Chemotherapy doses are usually prescribed on the basis of body surface area but dose banding is emerging as an efficient alternative. Dose banding presents the possibility of in-advance preparation in a Centralized Intravenous Admixture Service., Aim of the Study: To evaluate the long-term stability of 5-fluorouracil at banded doses (700 mg and 800 mg) in polyolefin bags., Materials and Methods: Ten polyolefin bags were prepared under aseptic conditions and stored at 23 ± 2°C for 24 days. Five of them were composed of 14 mL 5-fluorocuracil (700 g) in 100 mL 0.9% sodium chloride solution and the five other of 16 mL 5-fluorouracil (800 mg) in 100 mL 0.9% sodium chloride solution. At defined times, physical stability parameters were assessed: optical densities, pH measurements, visual and microscopical inspections. Solutions concentrations were measured using high-performance liquid chromatography coupled with a photodiode array detector., Results: No change was observed on pH and optical density measurements during the study period. Visual and microscopical inspections remained free of colour change, precipitate, microagregate or crystal. The concentrations of 5-Fluorouracil in 800 mg bags remained stable for 24 days while the concentration in 700 mg bags showed a stability of at least 17 days., Conclusion: Five-fluorouracil at banded doses of 700 and 800 mg in polyolefin bags is physicochemically stable for at least 17 days at 23 ± 2°C. These results support the possibility of in advance centralised preparation., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
22. An ultra-high-performance chromatography method to study the long term stability of gemcitabine in dose banding conditions.
- Author
-
Closset M, Colsoul ML, Goderniaux N, Bihin B, Jamart J, Onorati S, Soumoy L, Hecq JD, Odou P, and Galanti L
- Subjects
- Drug Stability, Drug Storage, Chromatography, High Pressure Liquid, Gemcitabine, Drug Packaging
- Abstract
Gemcitabine is an analogue of cytidine arabinoside, used alone or in combination chemotherapy to treat various type of cancer. The dose-banding of gemcitabine provides the opportunity to anticipate the preparation of this anticancer drug on condition of carrying out stability studies. The aim of this study is to develop and validate a stability-indicating ultra-high-performance Liquid Chromatography (UHPLC) method for measuring the concentration of gemcitabine and to evaluate its stability at standardised rounded doses in polyolefin bags. The UHPLC with photodiode array (PDA) detector method was developed and validated (linearity, precision, accuracy, limits of detection and quantification, robustness and degradation test). Thirty polyolefin bags of gemcitabine (1600 mg/292 ml (n = 10), 1800 mg/297 ml (n = 10) and 2000 mg/303 ml (n = 10)) were prepared under aseptic conditions and stored at 5 ± 3 °C and 23 ± 2 °C for 49 days. Physical stability tests were periodically performed: visual and microscopic inspection and optical densities. The chemical stability was evaluated through pH monitoring and chromatographic assays. The results confirm the stability of Gemcitabine at selected standardised rounded doses of 1600 mg, 1800 mg and 2000 mg in NaCl 0.9% polyolefin bags for at least 49 days at 5 ± 3 °C and 23 ± 2 °C, allowing in-advance preparation., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Evaluation of 30-days stability of morphine hydrochloride and clonidine at high and low concentrations in polypropylene syringes.
- Author
-
Catry E, Colsoul ML, Closset M, Nyssen C, Hubert J, Soumoy L, Bihin B, Jamart J, Hecq JD, and Galanti L
- Subjects
- Humans, Syringes, Analgesics, Opioid, Morphine Derivatives, Drug Stability, Clonidine, Polypropylenes
- Abstract
Objectives: Clonidine is an alpha-2 adrenoreceptor agonist and is frequently combined with opioids (ie, morphine hydrochloride (HCl)) for the management of chronic pain. In palliative care, the administration of clonidine and morphine HCl is recommended in case of tolerance effect. This study aimed to evaluate the physical and chemical stability of this admixture at high and low concentrations in 14 and 48 mL polypropylene syringes., Methods: The stability of a low concentration admixture of clonidine (Catapressan 0.15 mg/mL, Boehringer Ingelheim, Germany) and morphine (morphine HCl 40 mg/mL, Sterop, Belgium) at 0.003 and 0.417 mg/mL, respectively, was evaluated by using five polypropylene syringes of 48 mL. The high concentration admixture consisted of 0.032 mg/mL clonidine and 4.286 mg/mL morphine HCl and was evaluated by using five polypropylene syringes of 14 mL. All syringes were stored for 30 days at 5°C±3°C. Periodic samples were visually and microscopically examined to observe any particle appearance or colour change. pH and absorbance at three wavelengths (350, 410 and 550 nm) were monitored. The concentrations were measured by ultra-high performance liquid chromatography-photodiode array detection., Results: During the 30 days, there was no change in colour or appearance of opacity, turbidity or precipitation, and pH remained stable. The low and high concentration admixtures were considered chemically stable since the lower limit of the 90% CI remained superior to 90% of the initial concentration. Concentration measurements showed that the degradation rate was less than 1% over 10 days for each component in both admixtures., Conclusions: The admixture of clonidine and morphine HCl at low and high concentrations in polypropylene syringes appeared to be physically and chemically stable throughout the study period of 30 days at 5°C±3°C. In conclusion, the admixture can be prepared in advance under aseptic conditions by a centralised intravenous additive service in the pharmacy department., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
24. Bufalin for an innovative therapeutic approach against cancer.
- Author
-
Soumoy L, Ghanem GE, Saussez S, and Journe F
- Subjects
- Cell Line, Tumor, Cell Proliferation, Humans, Tumor Microenvironment, Amphibian Venoms pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Bufanolides pharmacology, Bufanolides therapeutic use, Cardiac Glycosides pharmacology, Neoplasms drug therapy
- Abstract
Bufalin is an endogenous cardiotonic steroid, first discovered in toad venom but also found in the plasma of healthy humans, with anti-tumour activities in different cancer types. The current review is focused on its mechanisms of action and highlights its very large spectrum of effects both in vitro and in vivo. All leads to the conclusion that bufalin mediates its effects by affecting all the hallmarks of cancer and seems restricted to cancer cells avoiding side effects. Bufalin decreases cancer cell proliferation by acting on the cell cycle and inducing different mechanisms of cell death including apoptosis, necroptosis, autophagy and senescence. Bufalin also moderates metastasis formation by blocking migration and invasion as well as angiogenesis and by inducing a phenotype switch towards differentiation and decreasing cancer cell stemness. Regarding its various mechanisms of action in cancer cells, bufalin blocks overactivated signalling pathways and modifies cell metabolism. Moreover, bufalin gained lately a huge interest in the field of drug resistance by both reversing various drug resistance mechanisms and affecting the immune microenvironment. Together, these data support bufalin as a quite promising new anti-cancer drug candidate., Competing Interests: Competing interests The authors have no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
25. Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine.
- Author
-
Catry E, Colsoul ML, Closset M, Hubert J, Soumoy L, Bihin B, Thiry E, Jamart J, Hecq JD, and Galanti L
- Subjects
- Chromatography, High Pressure Liquid, Drug Stability, Drug Storage, Humans, Pharmaceutical Preparations, Scopolamine, Syringes, Bumetanide, Polypropylenes chemistry
- Abstract
Death rattle, which could often be associated with a pulmonary fluid overload, occurs in 25% to 90% of dying patients. The co-administration of scopolamine (anticholinergic drug) and bumetanide (loop diuretic) could be considered in order to avoid unnecessary fluid overload at end-stage of life. The objective of this study was to investigate the physical and chemical stabilities of the admixture bumetanide and scopolamine in order to prepare them in advance by a centralized intravenous additive service in-hospital pharmacy. The stability of the lowest (LOW) concentration was evaluated on five polypropylene syringes containing the admixture bumetanide (Burinex, 2 mg/4 mL) and scopolamine (0.25 mg/mL) at 41.67 µg/mL and 5.21 µg/mL. The highest (HIGH) concentration with 125 µg/mL of bumetanide and 31.25 µg/mL of scopolamine was evaluated on five polypropylene syringes. All syringes were stored for 18 days at 5°C ± 3°C. Periodic samples were visually and microscopically examined to observe any particle appearance or color change. The pH and absorbance at 3 wavelengths (350 nm, 410 nm, and 550 nm) were monitored. The concentrations were measured by ultra-high performance liquid chromatography-photodiode array detection, using a newly developed method. During the 18 days of test, there was no change in color or appearance of opacity, turbidity, or precipitation, and the pH remained stable. Mean concentrations of bumetanide and scopolamine at LOW and HIGH concentrations after 18 days remained statistically unchanged. The lower limits of the 95% confidence intervals of both molecules at LOW and HIGH concentrations remained higher than a 90% threshold of concentration, indicating the mixture was chemically stable. Degradation rates of bumetanide and scopolamine content at LOW and HIGH concentrations should not exceed a maximum of 0.70% every 10 days. This study was the first to show that the admixture of bumetanide and scopolamine is physically and chemically stable at two concentrations used in a palliative-care unit. This combination available in ready-to-use polypropylene syringes presents numerous advantages for patient's comfort and safety., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2022
26. Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.
- Author
-
Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, and Ghanem GE
- Subjects
- Epigenesis, Genetic, Humans, Phenotype, Tumor Microenvironment, Melanoma pathology, MicroRNAs genetics
- Abstract
Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics. This phenotypic plasticity, which has gained more attention in cancer research, is proposed as a new paradigm for melanoma progression. In this review, we provide a detailed and deep comprehensive recapitulation of the complex spectrum of phenotype switching in melanoma, the key regulator factors, the various and new melanoma states, and corresponding signatures. We also present an extensive description of the role of epigenetic modifications (chromatin remodeling, methylation, and activities of long non-coding RNAs/miRNAs) and metabolic rewiring in the dynamic switch. Furthermore, we elucidate the main role of the crosstalk between the tumor microenvironment (TME) and oxidative stress in the regulation of the phenotype switching. Finally, we discuss in detail several rational therapeutic approaches, such as exploiting phenotype-specific and metabolic vulnerabilities and targeting components and signals of the TME, to improve the response of melanoma patients to treatments.
- Published
- 2022
- Full Text
- View/download PDF
27. Microwave Freeze-thaw Technique for Injectable Drugs: A Review Updated from 1980 to 2021.
- Author
-
Hecq JD, Soumoy L, Closset M, Colsoul ML, Jamart J, and Galanti L
- Subjects
- Drug Compounding, Drug Stability, Freezing, Microwaves, Pharmaceutical Preparations
- Abstract
The objective of this review was to collect information and results about the method of the microwave freeze-thaw treatment of injectable drugs and whether the method can support the development of Centralized Intravenous Admixtures Services. A systematic review of the scientific literature about injectable drug stability studies was performed. The data are presented in a table, which describes the name of the drug, producer, final concentration, temperature and time of freezing storage, type of microwave oven, thawing power, method of dosage, and the results after treatment or final long-term storage at 5°C ± 3°C. From 1980 to 2021, 60 drugs were studied by the microwave freeze-thaw treatment, and the results were presented in 49 publications. Forty papers were presented by 8 teams (2 to 18 by team). The temperatures of freezing storage varied from -70°C to -10°C, the time storage from 4 hours to 12 months, and the thaw from low to full power. Drug concentrations were mainly determined by high-performance liquid chromatography. Most of the 59 drugs were stable during and after treatment. Only three teams tested the long-term stability after the microwave freeze-thaw treatment, the first for ganciclovir after 7 days, the second for ceftizoxime after 30 days, and the third for 20 drugs after 11 to 70 days. This review can help Centralized Intravenous Additive Services take charge of the productions of ready-to-use injectable drugs., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2021
28. Compounding Robots for Intravenous Therapy in European Countries: A Review in 2020.
- Author
-
Hecq JD and Soumoy L
- Subjects
- Europe, Injections, Syringes, Robotics
- Abstract
A literature review was conducted in 2019 on the reconstitution of intravenous drugs. The following methods were identified: manual, semi-automatic, and automatic. A classification was carried out in three categories: automatic syringes, peristaltic pumps, and compounding doses robots. Data concerning the robots described in the previous review and possible robots that have appeared in the meantime were collected. The robots have been classified into 2 categories: with or without arms. The objective of the present review focuses on an updated review of the availability of compounding robots for intravenous therapy that are currently on the market., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2021
29. Long-term physico-chemical stability of 5-fluorouracile at standardised rounded doses (SRD) in MyFuser® portable infusion pump.
- Author
-
Closset M, Onorati S, Colsoul ML, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq JD, Odou P, and Galanti L
- Subjects
- Chemistry, Pharmaceutical, Drug Storage, Humans, Hydrogen-Ion Concentration, Antimetabolites, Antineoplastic chemistry, Drug Stability, Fluorouracil chemistry, Infusion Pumps
- Abstract
Management of chemotherapies is a strategic issue for european healthcare. Dose-banding enables to reduce waiting time of patients in day care units and drug wastage. The aim of this study was to assess the stability of 5-Fluorouracile (5-FU) at standardised rounded doses of 4 and 5 g in MyFuser® portable infusion pump for in-advance preparation. Ten MyFuser® (4 and 5 gr 5-FU added to NaCl 0.9%) were prepared under aseptic conditions and stored at room temperature (23 ± 2 °C) for 28 days then at 30 °C for three days. Physical stability tests were periodically performed: visual and microscopic inspection, pH measurements and optical densities. The concentration of solutions was measured by High Performance Liquid Chromatography/UV detector. Results confirm the stability of 5-FU at selected SRD of 4 g and 5 g with NaCl 0.9% in MyFuser® for at least 28 days at room temperature and three days at 30 °C, allowing in-advance preparation.
- Published
- 2021
- Full Text
- View/download PDF
30. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5±3°C.
- Author
-
Closset M, Goderniaux N, Colsoul ML, Soumoy L, Bihin B, Jamart J, Odou P, Hecq JD, and Galanti L
- Subjects
- Chromatography, High Pressure Liquid, Drug Packaging, Drug Stability, Drug Storage, Humans, Polyenes, Pyrrolidines, Ondansetron, Sodium Chloride
- Abstract
Background: Patients undergoing chemotherapeutic treatment are currently treated by a concomittent infusion of alizapride and ondansetron. To optimise the procedure and to ensure patients' safety, the admixture could be prepared in advance by the Centralized Intravenous Additive Service (CIVAS) provided that the stability of the mixture has been proven beforhand to reduce nausea and vomiting. Aim of the study: to evaluate the long-term stability of an admixture of alizapride 0.926 mg/l and ondansetron 0.074 mg/ml in 0.9% sodium chloride polyolefin bags stored at 5 ± 3°C., Material and Methods: Five polyolefin bags containing 100 ml sodium chloride 0.9% added with 4 ml alizapride (100 mg) and 4 ml ondansetron (8 mg) were prepared in aseptic conditions and stored at 5 ± 3°C for 56 days. Periodically, physical stability tests were performed including: pH measurements, optical density measurements at 350, 410 and 550 nm to track turbidity appearance, visual and microscopical inspections to detect colour changes, precipitation, microaggregates or crystals. The concentrations of the solutions were measured by High Performance Liquid Chromatography coupled with an UV detector., Results: There was no change in pH and optical densities during the study period. Visual and microscopical inspections didn't show any change of colour neither precipitation, microaggregate or crystal. The alizapride and ondansetron concentrations remained stable over the study., Conclusion: The admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags is physicochemically stable up to 56 days at 5 ± 3°C. These results support the possibility of preparing the solutions in advance by a CIVAS.
- Published
- 2021
- Full Text
- View/download PDF
31. Double-Decker Silsesquioxanes Self-Assembled in One-Dimensional Coordination Polymeric Nanofibers with Emission Properties.
- Author
-
Duszczak J, Mituła K, Santiago-Portillo A, Soumoy L, Rzonsowska M, Januszewski R, Fusaro L, Aprile C, and Dudziec B
- Abstract
The urgent needs for photoactive materials in industry drive fast evolution of synthetic procedures in many branches of chemistry, including the chemistry of silsesquioxanes. Here, we disclose an effective protocol for the synthesis of novel double-decker silsesquioxanes decorated with two (styrylethynylphenyl)terpyridine moieties ( DDSQ_Ta-b ). The synthesis strategy involves a series of silylative and Sonogashira coupling reactions and is reported for the first time. DDSQ_Ta-b were employed as nanocage ligands to promote self-assembly in the presence of transition metals (TM), i.e., Zn
2+ , Fe2+ , and Eu3+ ions, to form one-dimensional (1D) coordination polymeric nanofibers. Additionally, ultraviolet-promoted and reversible E - Z isomerization of the C═C bond within the ligand structures may be exploited to tune their emission properties. These findings render such complexes promising candidates for applications in materials chemistry. This is the first example of 1D coordination polymers bearing DDSQ-based nodes with TM ions.- Published
- 2021
- Full Text
- View/download PDF
32. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
- Author
-
Gheysen L, Soumoy L, Trelcat A, Verset L, Journe F, and Saussez S
- Subjects
- Animals, Antineoplastic Agents pharmacology, Calixarenes pharmacology, Cell Line, Tumor, Cell Proliferation, Focal Adhesion Kinase 2 metabolism, Galectin 1 antagonists & inhibitors, Heat-Shock Proteins metabolism, Humans, Male, Mice, Molecular Chaperones metabolism, Nitric Oxide Synthase Type III metabolism, Thyroid Neoplasms metabolism, Antineoplastic Agents therapeutic use, Calixarenes therapeutic use, Galectin 1 metabolism, Thyroid Neoplasms drug therapy
- Abstract
Although the overall survival rate of papillary or follicular thyroid cancers is good, anaplastic carcinomas and radio iodine refractory cancers remain a significant therapeutic challenge. Galectin-1 (Gal-1) is overexpressed in tumor cells and tumor-associated endothelial cells, and is broadly implicated in angiogenesis, cancer cell motility and invasion, and immune system escape. Our team has previously demonstrated a higher serum level of Gal-1 in patients with differentiated thyroid cancers versus healthy patients, and explored, by a knockdown strategy, the effect of Gal-1 silencing on cell proliferation and invasion in vitro, and on tumor and metastasis development in vivo. OTX008 is a calixarene derivative designed to bind the Gal-1 amphipathic β-sheet conformation and has previously demonstrated anti-proliferative and anti-invasive properties in several cancer cell lines including colon, breast, head and neck, and prostate cancer lines. In the current work, the impacts of OTX008 were evaluated in six thyroid cancer cell lines, and significant inhibitions of proliferation, migration, and invasion were observed in all lines expressing high Gal-1 levels. In addition, the signaling pathways affected by this drug were examined using RPPA (reverse phase protein array) and phosphoprotein expression assays, and opposite regulation of eNos, PYK2, and HSP27 by OTX008 was detected by comparing the two anaplastic lines 8505c and CAL 62. Finally, the sensitive 8505c line was xenografted in nude mice, and 3 weeks of OTX008 treatment (5 mg/kg/day) demonstrated a significant reduction in tumor and lung metastasize sizes without side effects. Overall, OXT008 showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1, supporting further investigation of the molecular mechanisms of the drug and future clinical trials in patients with anaplastic thyroid cancer.
- Published
- 2021
- Full Text
- View/download PDF
33. Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms.
- Author
-
Soumoy L, Wells M, Najem A, Krayem M, Ghanem G, Hambye S, Saussez S, Blankert B, and Journe F
- Abstract
Melanoma is the most common cancer in young adults, with a constantly increasing incidence. Metastatic melanoma is a very aggressive cancer with a 5-year survival rate of about 22-25%. This is, in most cases, due to a lack of therapies which are effective on the long term. Hence, it is crucial to find new therapeutic agents to increase patient survival. Toad venoms are a rich source of potentially pharmaceutically active compounds and studies have highlighted their possible effect on cancer cells. We focused on the venoms of two different toad species: Bufo bufo and Rhinella marina . We screened the venom crude extracts, the fractions from crude extracts and isolated biomolecules by studying their antiproliferative properties on melanoma cells aiming to determine the compound or the combination of compounds with the highest antiproliferative effect. Our results indicated strong antiproliferative capacities of toad venoms on melanoma cells. We found that these effects were mainly due to bufadienolides that are cardiotonic steroids potentially acting on the Na
+ /K+ ATPase pump which is overexpressed in melanoma. Finally, our results indicated that bufalin alone was the most interesting compound among the isolated bufadienolides because it had the highest antiproliferative activity on melanoma cells.- Published
- 2020
- Full Text
- View/download PDF
34. Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.
- Author
-
Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem GE, Saussez S, Colet JM, and Journe F
- Abstract
Treatments of metastatic melanoma underwent an impressive development over the past few years, with the emergence of small molecule inhibitors targeting mutated proteins, such as BRAF, NRAS, or cKIT. However, since a significant proportion of patients acquire resistance to these therapies, new strategies are currently being considered to overcome this issue. For this purpose, melanoma cell lines with mutant BRAF, NRAS, or cKIT and with acquired resistances to BRAF, MEK, or cKIT inhibitors, respectively, were investigated using both
1 H-NMR-based metabonomic and protein microarrays. The1 H-NMR profiles highlighted a similar go and return pattern in the metabolism of the BRAF, NRAS, and cKIT mutated cell lines. Indeed, melanoma cells exposed to mutation-specific inhibitors underwent metabolic disruptions following acute exposure but partially recovered their basal metabolism in long-term exposure, most likely acquiring resistance skills. The protein microarrays inquired about the potential cellular mechanisms used by the resistant cells to escape drug treatment, by showing decreased levels of proteins linked to the drug efficacy, especially in the downstream part of the MAPK signaling pathway. Integrating metabonomic and proteomic findings revealed some metabolic pathways (i.e., glutaminolysis, choline metabolism, glutathione production, glycolysis, oxidative phosphorylation) and key proteins (i.e., EPHA2, DUSP4, and HIF-1A) as potential targets to discard drug resistance.- Published
- 2020
- Full Text
- View/download PDF
35. Long-term stability of an infusion containing paracetamol, alizapride, ketorolac and tramadol in glass bottles at 5±3°C.
- Author
-
Colsoul ML, Hecq JD, Soumoy L, Charles O, Goderniaux N, Bihin B, Jamart J, and Galanti L
- Subjects
- Acetaminophen administration & dosage, Acetaminophen analysis, Analgesics, Non-Narcotic administration & dosage, Analgesics, Non-Narcotic analysis, Analgesics, Non-Narcotic chemistry, Analgesics, Opioid administration & dosage, Analgesics, Opioid analysis, Analgesics, Opioid chemistry, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal analysis, Anti-Inflammatory Agents, Non-Steroidal chemistry, Antiemetics administration & dosage, Antiemetics analysis, Antiemetics chemistry, Drug Packaging methods, Drug Stability, Drug Storage methods, Drug Storage standards, Glass analysis, Glass standards, Humans, Infusions, Intravenous, Ketorolac administration & dosage, Ketorolac analysis, Pharmaceutical Solutions administration & dosage, Pharmaceutical Solutions analysis, Pharmaceutical Solutions chemistry, Pyrrolidines administration & dosage, Pyrrolidines analysis, Time Factors, Tramadol administration & dosage, Tramadol analysis, Acetaminophen chemistry, Drug Packaging standards, Glass chemistry, Ketorolac chemistry, Pyrrolidines chemistry, Tramadol chemistry
- Abstract
Background and Objective: Infusion containing paracetamol, alizapride, ketorolac and tramadol is used after a general anaesthesia in order to limit pain, fever and nausea. Currently, these infusions are prepared according to demand in the anaesthesia unit, but the preparation in advance could improve quality of preparation and time management. The aim of this study was to investigate the long-term stability of this infusion in glass bottles at 5°C ± 3 °C., Method: Five bottles of infusion were stored at 5°C ± 3 °C for 60 days. A visual and microscope inspection were performed periodically to observe any particle appearance or colour change. pH and absorbance at three wavelengths were measured. The concentrations were measured by ultra-high performance liquid chromatography - diode array detection., Results: Multiple verifications were performed during the first 35 days and no crystal, impurity or colour change were observed. At the next time point (42nd day), crystals were visible to the naked eye. pH and absorbance at 350 nm and 550 nm were stable. A slight increase in the absorbance at 410 nm was observed during the study, suggesting that a degradation product could be formed and absorb at this wavelength. The infusion was considered chemically stable while the lower one-sided prediction limit at 95% remains superior to 90% of the initial concentration. Concentration measurements demonstrated that ketorolac and alizapride remained stable in the infusion for 35 days. The stability of tramadol was 28 days. However, degradation of paracetamol was much faster given that concentration has fallen below 90% of the initial concentration after 7 days., Conclusion: Infusion of paracetamol, alizapride, ketorolac and tramadol remains stable for 7 days in glass bottles at 5°C ± 3 °C and could be prepared in advance with these storage conditions., Competing Interests: Competing interests: None declared., (© European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
36. Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit.
- Author
-
Lardinois B, Dimitriou A, Delcave C, Soumoy L, Jamart J, Bihin B, Hecq JD, and Galanti LM
- Subjects
- Drug Stability, Drug Storage, Intensive Care Units, Isosorbide Dinitrate, Polypropylenes, Syringes
- Abstract
In order to avoid fluid overload, more concentrated drug solutions in intensive care units are commonly used. This study evaluated the physicochemical stability of concentrated solution of isosorbide dinitrate in polypropylene syringes during 28 days at 5°C ± 3°C with protection from light. Five syringes of 50 mL, containing 0.60 mg/mL of isosorbide dinitrate in sodium chloride 0.9% were prepared and stored at 5°C ± 3°C with protection from light during 28 days. Immediately after preparation and periodically during the storage, isosorbide dinitrate concentration was measured by an ultra-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurements, and microscopic observations were also performed. All solutions were physicochemically stable during the whole period storage at 5°C ± 3°C. No color change, turbidity, precipitation or opacity, significant pH variations, or optic densities were observed in the solutions. Any crystals were seen by microscopic analysis. The concentration of isosorbide dinitrate remained above 90% of the initial concentration during the 28 days of storage. Solutions of isosorbide dinitrate 0.60 mg/mL in syringe of sodium chloride 0.9 % injection can be considered physically and chemically stable for 28 days when stored in syringes at 5°C ± 3°C with protection from light and may be prepared in advance by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2020
37. Physical instability of an infusion containing ropivacaine, clonidine and adrenaline tartrate in syringes for pre-operative administration.
- Author
-
Colsoul ML, Lardinois B, Galanti L, Soumoy L, and Hecq JD
- Subjects
- Anesthetics, Local administration & dosage, Clonidine administration & dosage, Crystallization, Drug Stability, Drug Storage, Epinephrine administration & dosage, Humans, Hydrogen-Ion Concentration, Nephelometry and Turbidimetry, Ropivacaine administration & dosage, Syringes, Anesthetics, Local chemistry, Clonidine chemistry, Epinephrine chemistry, Preanesthetic Medication, Ropivacaine chemistry
- Published
- 2019
- Full Text
- View/download PDF
38. Long-term Physiochemical Stability of Concentrated Solutions of Salbutamol (Albuterol) in Polypropylene Syringes for Use in the Intensive Care Unit and in Obstetrics.
- Author
-
Lardinois B, Baltzis A, Delcave C, Soumoy L, Jamart J, Bihin B, Hecq JD, and Galanti L
- Subjects
- Albuterol, Chromatography, High Pressure Liquid, Intensive Care Units, Obstetrics, Polypropylenes chemistry, Syringes
- Abstract
In order to avoid fluid overload, the use of more concentrated drug solutions in intensive care units and obstetrics is common. The objective of this study was to quantify the physicochemical stability of a concentrated solution of salbutamol (albuterol) in polypropylene syringes during 30 days of storage at 5°C ± 3°C with protection from light. Four 50-mL syringes containing 0.060mg/mL of salbutamol (albuterol) in 0.9% NaCl were prepared and stored at 5°C ± 3°C with protection from light during 30 days of storage. Immediately after preparation and periodically during the storage, salbutamol (albuterol) concentrations were measured by an ultra-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurement, and microscopic observations were also performed. All solutions were physicochemically stable during the entire period of storage at 5°C ± 3°C: no color change, turbidity, precipitation or opacity, significant pH variations, or optic densities were observed in the solutions. No crystals were seen by microscopic analysis. Concentrations of salbutamol remained stable during the storage period. Solutions of salbutamol (albuterol) 0.060 mg/mL in syringes of 0.9% NaCl are physically and chemically stable for at least 30 days when stored in syringes at 5°C ± 3°C with protection from light and may be prepared in advance by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2019
39. Long-term Physicochemical Stability of Concentrated Solutions of Sodium Valproate in Polypropylene Syringes for Administration in the Intensive Care Unit.
- Author
-
Lardinois B, Baltzis A, Braibant M, Soumoy L, Jamart J, Bihin B, Hecq JD, and Galanti L
- Subjects
- Chromatography, High Pressure Liquid, Drug Storage, Intensive Care Units, Polypropylenes chemistry, Syringes, Valproic Acid
- Abstract
In some situations, drug solutions in higher concentrations are used in intensive care units. The objective of this study was to evaluate the physicochemical stability of concentrated solutions of valproate sodium in polypropylene syringes during 30 days at 5°C ± 3°C. Five syringes of 40 mL containing 20 mg/mL of sodium valproate in 0.9% sodium chloride were prepared and stored at 5°C ± 3°C during 30 days. Immediately after preparation and periodically during the storage, valproate concentrations were measured by high-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurement, and microscopic observations were also performed. All solutions were physically stable during the study period storage at 5°C ± 3°C. No color change, turbidity, precipitation, or opacity at visual observation was noticed. No significant pH variations or optic densities were observed. No crystals were seen by microscopic analysis. Concentrations of valproate remained stable during the period of storage. Solutions of sodium valproate 20 mg/mL in syringes of 0.9% sodium chloride were physically and chemically stable for at least 30 days when stored in syringes at 5°C ± 3°C. These solutions may be prepared in advance by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2019
40. Role of Macrophage Migration Inhibitory Factor (MIF) in Melanoma.
- Author
-
Soumoy L, Kindt N, Ghanem G, Saussez S, and Journe F
- Abstract
Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine involved in the carcinogenesis of many cancer types. Here, we review the published experimental and clinical data for MIF and its involvement in melanoma. All reported data show that MIF is overexpressed in melanoma cells, especially in case of metastatic disease. Clinical studies also indicate that high MIF expression is positively associated with aggressiveness of the disease. Some data also highlight the implication of MIF in angiogenesis, immunity and metastasis in melanoma cell lines, as well as the availability of different therapeutic options targeting MIF for the treatment of metastatic melanoma. Indeed, the main problem in metastatic melanoma is the lack of long-term effective treatment. This is linked to the capacity of melanoma cells to mutate very quickly and/or activate alternative signaling pathways. Thus, MIF targeting therapies could provide a new effective way of treating melanoma. Moreover, cell sensitivity to MIF depletion does not correlate with the BRAF mutational status. Regarding the fact that many melanoma patients carry a BRAF mutation, and that they develop resistance to BRAF inhibitors, this observation is very interesting as MIF inhibitors could be used to treat many patients in relapse after treatment with an inhibitor of the mutant BRAF protein.
- Published
- 2019
- Full Text
- View/download PDF
41. Evaluation of the Physicochemical Stability of Amiodarone Hydrochloride in Syringes for the Intensive Care Unit.
- Author
-
Lardinois B, Dimitriou A, Delcave C, Jamart J, Bihin B, Soumoy L, Hecq JD, and Galanti LM
- Subjects
- Chromatography, High Pressure Liquid, Drug Storage, Intensive Care Units, Syringes, Amiodarone, Drug Stability
- Abstract
In some emergency clinical situations, the injection of a more concentrated drug solution in the intensive care units is common. The purpose of this study was to evaluate the physicochemical stability of concentrated solutions of amiodarone hydrochloride in polypropylene syringes during 28 days of storage at 5°C ± 3°C, with protection from light. Five syringes of 50 mL, containing 25 mg/mL of amiodarone in dextrose 5%, were prepared and stored at 5°C ± 3°C with protection from light during 28 days. Immediately after preparation and periodically during the storage, amiodarone hydrochloride concentrations were measured by ultra-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurement, and microscopic observations were also performed. All solutions were physicochemically stable during the study period when stored at 5°C ± 3°C. No color change, turbidity, precipitation, opacity, significant pH variations, or optic densities were observed in the solutions. No crystals were seen by microscopic analysis. The concentration of amiodarone did not decrease during the 28 days of storage. Solutions of amiodarone 25 mg/mL in syringes of dextrose 5% are physically and chemically stable for at least 28 days when stored in syringes at 5°C ± 3°C with protection from light and may be prepared in advanced by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2019
42. Long-term Physicochemical Stability of Concentrated Solutions of Noradrenaline Bitartrate in Polypropylene Syringes for Administration in the Intensive Care Unit.
- Author
-
Lardinois B, Pector J, Delcave C, Soumoy L, Jamart J, Bihin B, Hecq JD, and Galanti LM
- Subjects
- Chemical Phenomena, Drug Stability, Hydrogen-Ion Concentration, Polypropylenes, Solutions, Syringes, Intensive Care Units, Norepinephrine chemistry
- Abstract
Intensive care units use drug solutions within higher concentrations to avoid fluid overload. The purpose of this study was to evaluate the physicochemical stability of concentrated solutions of noradrenaline bitartrate in polypropylene syringes during 30 days of storage at 5°C ± 3°C. Five 50-mL syringes containing 0.240 mg/mL of noradrenaline bitartrate in 0.9% sodium chloride were prepared and stored at 5°C ± 3°C during 30 days. Immediately after preparation and periodically during the storage, noradrenaline concentrations were measured by high-performance liquid chromatography. Spectrophotometric absorbance at different wavelengths, pH measurement, and microscopic observations were also performed. The results showed that all solutions were physicochemically stable during the entire storage period at 5°C ± 3°C, and no color change, turbidity, precipitation, opacity, significant pH variations, nor optic densities were observed. Microscopic analysis was used to determine if there was any formation of crystals. The concentration of noradrenaline was not found to decrease during the 30 days of storage. Solutions of noradrenaline bitartrate 0.240 mg/mL in syringes of 0.9% sodium chloride were physically and chemically stable for at least 30 days when stored in syringes at 5°C ± 3°C and may be prepared in advanced by a centralized intravenous additive service., (Copyright© by International Journal of Pharmaceutical Compounding, Inc.)
- Published
- 2018
43. [Preliminary study for the implementation of standardized rounded doses of cytotoxic druqs].
- Author
-
Soumoy L, Pirlot C, Decoster C, Gillet P, and Hecq JD
- Subjects
- Antineoplastic Combined Chemotherapy Protocols administration & dosage, Chemistry, Pharmaceutical, Drug Prescriptions standards, Humans, Neoplasms drug therapy, Pharmacy Service, Hospital standards, Retrospective Studies, Antineoplastic Agents administration & dosage
- Abstract
Background: "Dose-banding" is a concept of cytotoxic drugs standardization allowing the preparation in advance of standardized rounded doses (SRD covering the most frequently prescribed doses rounded to +/-5%. Standard doses will be prepared in advance by batch in order to increase production capacity and at the same time to regulate pharmacy workflow as well as to reduce patient waiting time., Purpose: To identify anticancer drugs suitable for dose banding and to fix standardized doses., Methods: The interesting molecules are first selected in accordance with several criteria: preparations frequency, long-term physicochemical stability after reconstitution, repetition of the prescribed doses and savings opportunity. The selected molecules were: Carboplatin, Cetuximab, Cisplatin, Cyclophosphamide, Doxorubicin, 5-Fluorouracil, Gemcitabine, Oxaliplatine, Paclitaxel, Rituximab, Trastuzumab and Vinorelbine. We established an inventory of the prescriptions retrospectively for a period of six months in order to highlight the most often prescribed doses. For the analysis, we fixed bands with a standard deviation of +/- 5%, 7% and +/- 10%., Results: Standardization of doses of chemotherapy was deemed interesting if > or =60% of the doses were standardisable with a maximum of five SRD and a minimum of one delivery per week, in order to guarantee a good turnover of the batch. A maximum of 5% standard deviation is added to those three criteria, the deviation currently accepted among our medical staff. After analyzing 3506 prescriptions, 7 molecules are eligible: Doxorubicine, 5-Fluorouracil infusion, 5-Fluorouracil pump, Gemcitabine, Paclitaxel, Rituximab, Trastuzumab and Vinorelbine, with a percentage of standardisation of 77% [SRD: 30 mg), 61% [SRD: 700 mg, 750 mg, 800 mgl, 75% (SRD: 4000 mg, 4500 mg, 5000 mg), 72% [SRD: 1600 mg, 1800 mg, 2000 mg), 61% [SRD: 140 mg, 150 mg, 160 mgl, 64% (SRD: 600 mg, 700 mg, 750 mg], 71% (SRD: 350 mg, 400 mg. 450 mgl et 62% [SRD: 40 mg, 50 mg] respectively., Conclusion: This preliminary study allows us to consider implementing the dose banding concept in order to optimize the chemotherapy circuit at our institution.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.